M3 Biotechnology launches first-in-human trial of NDX-1017 and raises $15.2M to fund Alzheimer’s program

M3 Biotechnology launched a first-in-human clinical trial for its Alzheimer’s candidate NDX-1017, which the company says could slow, halt, or potentially restore neuron damage, and raised $15.2 million to support the effort, bringing total funding above $26 million.

No comments yet.